Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: Fitz who wrote (20699)	5/22/1998 10:02:00 AM
From: Leman	Respond to of 34592

HYALF patents 5674857 Use of hyaluronic acid to repair ischemia reperfusion damage 80% 5639738 Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs 80% 5614506 Use of hyaluronic acid and forms to prevent arterial restenosis 80% 5079236 Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use 80% 5077296 Method for treating equine navicular disease with pentoxifylline, and composition containing pentoxifylline for administrating to horses 80% 5039521 Immune cell proliferation inhibitors From the recent quarterly...... "31,703,780 common shares and US$4.9 million in debentures outstanding at April 17, 1998 and cash of $9.4 million (US $6.6 million) at March 31, 1998". I don't see anything scary there, but they will need funding ('97 burn was C$19 million) soon. Eva Turley, their V.P. R&D, is a very respected scientist.